In late 2019, Gustav Eyler, the Director of the U.S. Department of Justice’s (“DOJ”) Consumer Protection Branch (“CPB”), cited fraudulent data in clinical research trials for new drugs and medical devices as a topic of “major...more
3/23/2021
/ Clinical Laboratory Testing ,
Clinical Trials ,
Coronavirus/COVID-19 ,
Corruption ,
Criminal Prosecution ,
Department of Justice (DOJ) ,
Enforcement ,
False Statements ,
Food and Drug Administration (FDA) ,
Fraud ,
Medical Devices ,
Medical Research ,
Pharmaceutical Industry ,
Popular ,
Willful Misconduct ,
Wire Fraud